Infliximab for the treatment of neuro-Behcet's disease: A case series and review of the literature
Infliximab for the treatment of neuro-Behcet's disease: A case series and review of the literature
复制标题
DOI：
10.1002/art.23345
复制
发表时间：
2008-02-15
期刊：
影响因子：
--
通讯作者：
Salvarani, Carlo
中科院分区：
文献类型：
--
作者：
Pipitone, Nicolo;Olivieri, Ignazio;Salvarani, Carlo
BEHçet‘s病(BD)是一种以口腔和生殖器溃疡为特征的血管炎。实质性中枢神经系统受累是一种严重的并发症，通常以脑干和/或基底节损害为特征。到目前为止，神经白塞氏病的治疗主要仍是经验性的，可能不能充分控制疾病(1)。血清肿瘤坏死因子α(肿瘤坏死因子α)水平在活动期BD(2)升高，提示肿瘤坏死因子α在疾病发病机制中的作用。临床上，肿瘤坏死因子α阻断可显著改善BD的各种表现(3)。然而，关于肿瘤坏死因子α阻滞剂治疗神经白塞氏症的有效性的证据很少。我们报告了8名对英夫利昔单抗治疗反应良好的神经白塞氏症患者，并回顾了相关文献。
Behçet’s disease (BD) is a vasculitis in which the hallmark lesions are oral and often genital ulcers. Involvement of parenchymal central nervous system (neuro-Behçet’s) is a serious complication commonly characterized by brainstem and/or basal ganglia lesions. To date, treatment of neuro-Behçet’s remains largely empirical, and may not adequately control the disease (1). Serum tumor necrosis factor α (TNFα) levels are increased in active BD (2), suggesting a role for TNFα in disease pathogenesis. Clinically, significant improvement of various BD manifestations has been reported with TNFα blockade (3). However, evidence for the efficacy of TNFα blockers in the treatment of neuro-Behçet’s is scant. We present 8 patients with neuro-Behçet’s who responded favorably to infliximab therapy and review the relevant literature.